Results 21 - 30 of 258 : Previous 1 2 3 4 5 6 7 8 9 Next
Will a Better Drug Sell Better?
Positive trial data isn't enough to significantly boost Johnson & Johnson's Remicade.
Great Call on Goldman Sachs! What's Next?
This Fool made a great call on Goldman Sachs -- check out the other moves he has been making.
A few signals that Pfizer might be the one bidding on ImClone.
InterMune Previews a Coming Attraction
Early data on its new hepatitis C compound looks good -- for now.
The company's potential hepatitis C compound proves effective with fewer dosages.
One Share Offering Too Many for Vertex?
Vertex raises cash again by diluting itself.
Schering is cutting jobs. Maybe the government should help out?
J&J's psoriasis drug candidate beats Amgen and Wyeth's Enbrel.
Ranbaxy's Troubles Won't Help Competitors
It may be hard to get a hit in with so much competition kicking Ranbaxy while it's down.
Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK